AN OPEN-LABEL, 6-MONTH OBSERVATIONAL STUDY OF PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS RECEIVING RISPERIDONE LONG ACTING INJECTION

被引：0
|
作者：
Hustig, Harry [1 ]
Newton, Richard [2 ]
Nyst, Phil [3 ]
机构：
[1] Glenside Hosp, Eastwood, SA, Australia
[2] Frankston Hosp, Frankston, Vic, Australia
[3] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia
来源：
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：A56 / A56
页数：1
相关论文
共 50 条
  • [21] The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable
    Gharabawi, Georges
    Bossie, Cynthia
    Turkoz, Ibrahim
    Kujawa, Mary
    Mahmoud, Ramy
    Simpson, George
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2007, 195 (12) : 976 - 982
  • [22] Improvement in personal and social functioning in schizophrenia patients treated with risperidone long acting injection): 6-month results from E-star
    Pecenak, J.
    Tuma, I
    De groot-stam, E.
    Eriksson, L.
    Bork, B.
    Ligate, L.
    Povey, M.
    Lam, A.
    Trakas, K.
    Zhao, Z.
    VALUE IN HEALTH, 2008, 11 (03) : A127 - A127
  • [23] A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea
    Lee, Nam Young
    Kim, Se Hyun
    Cho, Seong Jin
    Chung, Young-Cho
    Jung, In Kwa
    Kim, Chang Yoon
    Kim, Duk Ho
    Lee, Dong Geun
    Lee, Yo Han
    Lim, Weon Jeong
    Na, Young Suk
    Shin, Sang Eun
    Woo, Jong-Min
    Yoon, Jin Sang
    Yoon, Bo-Hyun
    Ahn, Yong Min
    Kim, Yong Sik
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (05) : 279 - 287
  • [24] Safety and Effectiveness of SEP-363856 in Schizophrenia: Results of a 6-Month, Open-Label Extension Study
    Correll, Christoph
    Koblan, Kenneth
    Hopkins, Seth
    Kent, Justine
    Cheng, Hailong
    Goldman, Robert
    Loebel, Antony
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 494 - 495
  • [25] Risperidone -: An open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia
    Pajonk, FG
    Schreiner, A
    Peters, S
    Rettig, K
    Degner, D
    Rüther, E
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2005, 25 (04) : 293 - 300
  • [26] An open-label, 6-month study of allopurinol safety in gout: The LASSO study
    Becker, Michael A.
    Fitz-Patrick, David
    Choi, Hyon K.
    Dalbeth, Nicola
    Storgard, Chris
    Cravets, Matt
    Baumgartner, Scott
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2015, 45 (02) : 174 - 183
  • [27] Duloxetine for patients with diabetic peripheral neuropathic pain: A 6-month open-label safety study
    Raskin, Joel
    Wang, Fujun
    Pritchett, Yili Lu
    Goldstein, David J.
    PAIN MEDICINE, 2006, 7 (05) : 373 - 385
  • [28] Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic
    Fleischhacker, WW
    Eerdekens, M
    Karcher, K
    Remington, G
    Llorca, PM
    Chrzanowski, W
    Martin, S
    Gefvert, O
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) : 1250 - 1257
  • [29] A 6-month open-label study of the effectiveness and tolerability of galantamine in patients with Alzheimer's disease
    Patterson, CE
    Passmore, AP
    Crawford, VLS
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (02) : 144 - 148
  • [30] Long-term efficacy and safety of paliperidone 6-month formulation: An open-label extension of a double-blind study in adult patients with schizophrenia
    Najarian, D.
    Turkoz, I.
    Galderisi, S.
    Lamaison, H. F.
    Zalitacz, P.
    Aravind, S.
    Richarz, U.
    EUROPEAN PSYCHIATRY, 2023, 66 : S136 - S136
12345